Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses the combination of temozolomide and capecitabine in neuroendocrine tumors (NETs).
Jodie Barr, DO
Advertisement
Articles by Jodie Barr, DO
Jodie Barr, DO, hematologist/oncologist, Lawrence Memorial Hospital, discusses systemic therapies for patients with neuroendocrine tumors (NETs).
I can remember waiting anxiously on match day; checking the computer every few seconds to see if I matched.
Advertisement
Latest Updated Articles
Dr. Barr on Systemic Therapies for Patients With Neuroendocrine TumorsPublished: July 4th 2018 | Updated:
- Dr. Barr on Temozolomide and Capecitabine in Neuroendocrine Tumors
Published: July 17th 2018 | Updated:
Life as a First-Year FellowPublished: April 10th 2014 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5